Clinical Trial Update: Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique. [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Respimat inhaler to a hydrochlorofluorocarbon metered-dose inhaler (HFA MDI) using Berodual in COPD patients with poor MDI technique.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Berodual (ipratropium bromide + fenoterol)
• Respimat

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive, Asthma | Phase 4 | Status: COMPLETED